BR0107893A - Agonistas e antagonistas de receptor de melanocortina - Google Patents

Agonistas e antagonistas de receptor de melanocortina

Info

Publication number
BR0107893A
BR0107893A BR0107893-3A BR0107893A BR0107893A BR 0107893 A BR0107893 A BR 0107893A BR 0107893 A BR0107893 A BR 0107893A BR 0107893 A BR0107893 A BR 0107893A
Authority
BR
Brazil
Prior art keywords
antagonists
receptor agonists
melanocortin receptor
melanocortin
amines
Prior art date
Application number
BR0107893-3A
Other languages
English (en)
Inventor
Torbjoern Lundstedt
Anna Skottner
Elisabeth Seifert
Igor Starchenkov
Peteris Trapencieris
Valerjans Kauss
Ivars Kalvinsh
Arne Boman
Original Assignee
Melacure Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002060A external-priority patent/GB0002060D0/en
Priority claimed from GB0001948A external-priority patent/GB0001948D0/en
Application filed by Melacure Therapeutics Ab filed Critical Melacure Therapeutics Ab
Publication of BR0107893A publication Critical patent/BR0107893A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)

Abstract

"AGONISTAS E ANTAGONISTAS DE RECEPTOR DE MELANOCORTINA". Novos agonistas e antagonistas de receptor de melanocortina. A presente invenção refere-se a aminas aromáticas de fórmula geral (I) e ao uso destas aminas para o tratamento de obesidade, anorexia, inflamação, distúrbios mentais, e outras doenças associadas com os receptores de melanocortina ou sistemas relacionados, por exemplo os hormónios estimulando melanócitos.
BR0107893-3A 2000-01-28 2001-01-29 Agonistas e antagonistas de receptor de melanocortina BR0107893A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0002060A GB0002060D0 (en) 2000-01-28 2000-01-28 Novel aromatic amines
GB0001948A GB0001948D0 (en) 2000-01-28 2000-01-28 Novel aromatic amines
PCT/GB2001/000346 WO2001055106A2 (en) 2000-01-28 2001-01-29 Novel melanocortin receptor agonists and antagonists

Publications (1)

Publication Number Publication Date
BR0107893A true BR0107893A (pt) 2002-11-05

Family

ID=26243502

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107893-3A BR0107893A (pt) 2000-01-28 2001-01-29 Agonistas e antagonistas de receptor de melanocortina

Country Status (10)

Country Link
US (1) US20030195212A1 (pt)
EP (1) EP1254114A2 (pt)
JP (1) JP2003520850A (pt)
KR (1) KR20020075396A (pt)
AU (1) AU2001228677A1 (pt)
BR (1) BR0107893A (pt)
CA (1) CA2398728A1 (pt)
IL (1) IL150898A0 (pt)
MX (1) MXPA02007289A (pt)
WO (1) WO2001055106A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
EP1767525A1 (en) 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
EP1425029A4 (en) 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
WO2003057671A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Compose biaryle et son utilisation
ATE478867T1 (de) 2002-05-23 2010-09-15 Novartis Vaccines & Diagnostic Substituierte quinazolinone verbindungen
TW200420559A (en) * 2002-11-19 2004-10-16 Takeda Chemical Industries Ltd Amine compounds and method for producing the same
EP1572647B1 (en) * 2002-12-20 2016-09-21 Basf Se Synthesis of amines and intermediates for the synthesis thereof
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
KR20060018217A (ko) 2003-05-23 2006-02-28 카이론 코포레이션 Ｍｃ4-ｒ 작용제로서 구아니디노-치환된 퀴나졸리논 화합물
KR20060105785A (ko) 2003-11-19 2006-10-11 카이론 코포레이션 감소된 생체축적을 갖는 퀴나졸리논 화합물
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
ATE498678T1 (de) 2004-04-08 2011-03-15 Astellas Pharma Inc Verbindung ws727713
AU2005231034B2 (en) * 2004-04-08 2010-04-08 Telsar Pharma Inc. Compound WS727713
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
EP1765347A4 (en) * 2004-06-04 2008-10-01 Univ California COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE
DE602007014363D1 (de) 2006-06-09 2011-06-16 Action Pharma As Phenylpyrrolaminoguanidinderivate
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
GB0624987D0 (en) 2006-12-14 2007-01-24 Acure Pharma Ab Novel aminoguanidines as melanocortin receptor ligands
WO2008107335A1 (en) * 2007-03-05 2008-09-12 F. Hoffmann-La Roche Ag Aminoamides as orexin antagonists
KR100878446B1 (ko) * 2007-06-07 2009-01-13 일동제약주식회사 신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법
WO2009051910A1 (en) * 2007-10-16 2009-04-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
WO2012135615A2 (en) 2011-03-30 2012-10-04 Brown University Enopeptins, uses thereof, and methods of synthesis thereto
MX2013015274A (es) 2011-06-24 2014-03-31 Amgen Inc Anatagonista trpm8 y su uso en tratamientos.
JP2014517074A (ja) 2011-06-24 2014-07-17 アムジエン・インコーポレーテツド Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
EP2923700B1 (en) * 2012-11-26 2018-11-07 Tohoku University Erythropoietin expression promoter
JP6280912B2 (ja) 2013-03-14 2018-02-14 武田薬品工業株式会社 複素環化合物
US10472376B2 (en) 2013-07-03 2019-11-12 Takeda Pharmaceutical Company Limited Amide compound
US10053468B2 (en) 2013-07-03 2018-08-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6372817B2 (ja) * 2014-03-27 2018-08-15 国立大学法人東北大学 臓器線維化抑制剤
WO2016037072A2 (en) * 2014-09-04 2016-03-10 Brown University Enopeptin analogas and methods of use thereof
UA125800C2 (uk) * 2017-06-30 2022-06-08 Баєр Енімал Хелс Гмбх Похідні азахіноліну
WO2020257662A1 (en) * 2019-06-19 2020-12-24 The Regents Of The University Of Michigan Targeting melanocortin 3 receptor for treatment/prevention of eating, metabolism, and/or emotional disorders
CN117980302A (zh) * 2021-08-10 2024-05-03 德克萨斯心脏研究所 Lfa-1和vla-4的基于哌嗪的激动剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3768799A (en) * 1998-04-28 1999-11-16 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same

Also Published As

Publication number Publication date
US20030195212A1 (en) 2003-10-16
MXPA02007289A (es) 2003-09-22
IL150898A0 (en) 2003-02-12
JP2003520850A (ja) 2003-07-08
AU2001228677A1 (en) 2001-08-07
EP1254114A2 (en) 2002-11-06
KR20020075396A (ko) 2002-10-04
WO2001055106A2 (en) 2001-08-02
CA2398728A1 (en) 2001-08-02
WO2001055106A3 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
BR0107893A (pt) Agonistas e antagonistas de receptor de melanocortina
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
BR0010138A (pt) Moduladores de receptores de glucocorticóides
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
BR0010651A (pt) Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
BR0312758A (pt) Derivados de 1-heterociclilalquil-3-sulfonilazaindol ou -azaindazol como ligantes da 5-hidroxitriptamina-6
BRPI0410731A (pt) composto, composição farmacêutica, métodos para agonizar o receptor mc4, para tratar obesidade, para tratar diabetes melito e para tratar disfunção sexual masculina e/ou feminina em um mamìfero, e, uso de um composto
UY26291A1 (es) Compuestos químicos xxii
WO2001055107A3 (en) Aromatic amines and amides acting on the melanocortin receptors
BR0009320A (pt) Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
BR0212986A (pt) Derivados de imizadol-4-carboxamida, preparação e uso dos mesmos para tratamento de obesidade
BR0104831A (pt) Moduladores de receptor de glucocorticóide
PA8493701A1 (es) Compuestos para tratar la obesidad
BR0209580A (pt) Derivados de ciclohexan-1, 4 diamina substituìdos
BR0309544A (pt) Preparação farmacêutica contendo oxicodona e naloxona
UY27983A1 (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
BR0209047A (pt) Derivados de heterociclilalcóxi-, -alquiltio- e -alquilaminobenzazol como ligantes de 5-hidroxitriptamina-6
BRPI0414386A (pt) composto, métodos para fabricação do mesmo, para tratamento ou prevenção de uma doença, para ativação da função de er em uma célula óssea, para inibição de função de er em uma célula, para inibição da expressão de il-6, para inibição do crescimento de uma célula neoplásica expressando er, para prevenção de espermatogenese, para prevenção de um efeito reprodutivo adverso associados com exposição a uma falta de equilìbrio hormonal natural ou quìmica ambiental, e, composição
NO996442D0 (no) Anvendelse av en spesifikk antagonist for 5HT2 reseptorer for fremstilling av medisiner som er anvendbare for behandling av forstyrret pusting under søvn
ES2171196T3 (es) Uso de antagonistas del receptor cck-b para el tratamiento de trastornos del sueño.
BR9815335A (pt) Uso de antagonistas de receptor de endotelina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.